Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: R 848; S 28463; VML 600

Latest Information Update: 21 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Spirig Pharma
  • Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Actinic keratosis; Basal cell cancer; Hepatitis C; Herpes simplex virus infections; Immunological disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Oct 2013 Spirig Pharma discontinues a phase II trial in Basal cell carcinoma in Germany (NCT01808950)
  • 04 Sep 2013 Spirig Pharma discontinues a phase II trial in Actinic keratosis in Germany and Switzerland (NCT01806961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top